Sartorius

Loading...

Filtration systems:

Tangential Flow Filtration (TFF) Solutions

Tangential Flow Filtration Systems

Sartorius Stedim Biotech GmbH

Notice

The supplier currently does not offer direct contact options for quotes or information requests for this product. You can find similar products in our Product directory filters.

The Sartoflow Smart is a flexible small-scale benchtop ...

Sartorius offers a range of flexible tangential flow filtration (TFF) systems and consumables for process development and clinical trials, from laboratory environments to commercial production batches. These systems can be configured to accommodate individual requirements, including cost-efficient multi-user systems or closed systems with single-use flow kits for aseptic processing.

The Sartoflow Smart is a flexible small-scale benchtop TFF system suited for scaling studies and low-volume UF | DF work over a wide range of surface areas, from 50 cm² to as much as 0.14 m².

The Sartoflow Advanced is a highly automated modular benchtop crossflow system optimized for ultrafiltration, microfiltration, and diafiltration. It has two pumps for feed and buffer addition and full TMP control.

Both systems can be used in the downstream purification of vaccines, monoclonal antibodies, and recombinant proteins and provide options to customize the system to your specific requirements. In addition, the corresponding TFF cassettes offer a range of filtration areas and molecular weight cut-offs.

Last viewed contents

Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million

Siegfried begins construction of new large-scale production plant in Minden (DE) - Total investment of up to CHF 100 million

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK - Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth

Waters Corporation Opens State-of-the-Art Precision Manufacturing Facility in Longbridge, UK - Waters triples manufacturing footprint while increasing precision machining and metrology capacity to support future growth

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Simtra BioPharma Solutions - Parsippany, USA

Simtra BioPharma Solutions - Parsippany, USA

Boehringer Ingelheim to acquire NBE-Therapeutics - Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Boehringer Ingelheim to acquire NBE-Therapeutics - Boehringer Ingelheim Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

European Medicines Agency recommends that Linoladiol N and Linoladiol HN remain available - Benefits continue to outweigh risks with new restrictions

Advises on compassionate use of a new combination therapy for chronic hepatitis C - Combination of ledipasvir and sofosbuvir to be used in patients in urgent need of therapy to prevent progression of liver disease

EMA recommends approval of new treatment for platinum-resistant ovarian cancer - Vynfinit (vintafolide) offers treatment for women with limited therapeutic options; two diagnostic medicines recommended for approval will help identify patients most likely to respond

EMA endorses revised policy on handling of declarations of interests

Recommendation against combined use of medicines affecting the renin-angiotensin system